Somewhere on the internet, a hot take is doing cardio: “Chemo doesn’t work.” It’s usually delivered with the confidence of a man explaining
how to grill a steak while holding the steak upside down. The claim often comes with a suspiciously neat statistic (the infamous “2%” line),
a dramatic meme, and a sales pitch for something “natural” thatshockinglycan be purchased right now.
But in real oncology, “works” is not a single yes/no switch. Chemotherapy is a broad category of drugs used in different ways for different cancers,
at different stages, with different goals: cure, longer survival, shrinking tumors before surgery, reducing the chance of recurrence, or easing symptoms.
When you define the goal precisely, the question becomes more honestand the answers get a lot more interesting.
First, let’s define “chemotherapy” like adults
“Chemotherapy” isn’t one medication. It’s a family of drug classes that attack cancer cells (and other fast-dividing cells) in different waysby
damaging DNA, blocking cell division, or interfering with cell metabolism. Some chemotherapy is given alone, but much of modern cancer care uses it
as part of a plan with surgery, radiation, targeted therapy, immunotherapy, or hormone therapy.
That matters because the internet tends to argue like this:
- Claim: “Chemo failed for my uncle’s late-stage cancer.”
- Conclusion: “Therefore chemo is useless for everyone.”
That’s like saying seatbelts don’t work because a car hit a meteor. Cancer stage, tumor biology, and treatment intent completely change what “success”
looks like.
The “2% gambit”: where the meme number comes from
One of the most common rhetorical tricks is the “2% gambit”the claim that chemotherapy “only works 2% of the time.” This is often traced back to a
paper that estimated the contribution of cytotoxic chemotherapy to 5-year survival in adults as roughly ~2% in the U.S. and Australia.
That estimate has been widely criticized for its methodology and for being repeatedly misused far beyond what it can actually claim.
Why the “2%” framing is misleading
Even if you take the paper at face value, the “2%” number is not “chemo response rate,” not “chance chemo helps an individual,” and not “chance chemo
cures cancer.” It’s a population-level estimate of contribution to 5-year survival using specific assumptions and selected cancers, focused on
older regimens and on cytotoxic chemotherapy (not the full universe of modern systemic therapy).
More importantly, the number becomes internet confetti when it’s applied to:
- cancers where chemo is often curative (or contributes substantially to cure),
- situations where chemo is used to reduce recurrence risk (adjuvant therapy),
- advanced cancers where the goal is living longer or better, not necessarily crossing a 5-year finish line,
- and modern care, which includes better supportive meds, improved dosing strategies, and entirely new drug classes.
In other words: “2%” is a statistic with a narrow definition that’s regularly treated like a universal truth. That’s not analysisit’s marketing.
Science-Based Medicine has dissected how this figure gets recycled by cancer quackery for exactly that reason.
So… does chemotherapy work? Yeswhen it’s used for the right job
The most useful way to answer the question is to separate chemo’s roles. Here are the big ones:
1) Curative chemotherapy: when the goal is to wipe out cancer
Some cancers are famously chemo-sensitive, and chemotherapy is a major reason cure rates became what they are today.
A classic example is testicular cancer: the introduction of cisplatin-based combination therapy transformed outcomes, with cure rates
exceeding 90% in many settingsone of the great success stories of modern cancer treatment.
Another example: childhood acute lymphoblastic leukemia (ALL). Survival has climbed dramatically over the decades; modern treatment protocolsoften built
around chemotherapy combinationshave pushed 5-year survival to around 90% for many children. That’s not a rounding error. That’s thousands of kids
growing up to complain about homework like everyone else.
2) Adjuvant chemotherapy: the “seed cleanup” after the big job
Sometimes surgery removes the visible tumor, but microscopic cancer cells may remain. Adjuvant chemotherapy is used after surgery to reduce the risk of
recurrenceespecially in cancers where studies show it improves outcomes.
A well-known example is stage III colon cancer, where adjuvant chemotherapy (often oxaliplatin plus a fluoropyrimidine) has been a standard approach.
The point isn’t that chemo is magical; it’s that the evidence shows it can improve survival in that context, and oncologists make treatment plans around
risk and benefit.
3) Neoadjuvant chemotherapy: shrink it before the main event
In some cases, chemotherapy is used before surgery or radiation to shrink a tumor, make surgery easier, or improve the odds of controlling
disease locally and systemically. It’s not “chemo as a last resort.” It’s chemo as a strategic opening move.
4) Palliative chemotherapy: when “working” means time and quality of life
In metastatic or otherwise advanced cancers, chemotherapy is often used to slow progression, reduce symptoms, and extend lifesometimes substantially,
sometimes modestly. It may not produce a cure, but that doesn’t make it “not working.” If a regimen shrinks tumors, reduces pain, improves breathing,
or gives someone meaningful extra time with fewer symptoms, that is a clinical win.
The internet loves simple endings. Real life is messier: some cancers become resistant, some people can’t tolerate a regimen, and some treatments help
only a subset of patients. Oncology is the art of matching the right patient to the right toolthen measuring whether it’s achieving the intended goal.
Why “chemo failed” stories spread faster than “chemo worked” stories
There are human reasons this myth persists, even among well-meaning people:
- Availability bias: We remember dramatic losses. Survivors often return to normal life and stop posting updates.
- Stage confusion: Many people encounter chemotherapy only when cancer is advancedwhen the goal is control, not cure.
- Side effects are visible: Hair loss and nausea are obvious. “Tumor cells died on schedule” is not.
- Bad actors exploit fear: Cancer is terrifying, and fear is a profitable business model.
Yes, chemotherapy can be brutaland that’s part of the truth, too
It’s also important not to swing into cheerleading. Chemotherapy can cause serious side effects: fatigue, nausea, vomiting, mouth sores, hair loss,
low blood counts (raising infection risk), neuropathy, fertility issues, and more. These risks are real, and the decision to use chemotherapy should
always be individualized.
The “good news” (which can feel like a weird phrase in oncology, but stay with me) is that supportive care has improved enormously. Modern antiemetic
guidelines, for example, have helped clinicians prevent and manage chemotherapy-induced nausea and vomiting far more effectively than in past decades.
Growth-factor support, infection prevention strategies, and better dosing approaches have also improved the safety profile for many patients.
What cancer outcomes actually tell us: progress comes from multiple angles
Cancer death rates in the U.S. have declined substantially from their early-1990s peak. That progress is driven by a combination of prevention (like
reduced smoking), screening and early detection, and treatment advances. Importantly, treatment isn’t the only hero in the storybut it is absolutely
a hero in many chapters. The real lesson is not “chemo saved everyone.” It’s “evidence-based medicine stacks improvements.”
And treatment keeps evolving. Today’s cancer care increasingly combines classic chemotherapy with targeted drugs, antibody-drug conjugates, and
immunotherapiessometimes using chemo as a backbone, sometimes replacing it, often tailoring decisions based on biomarkers.
How to spot misinformation about chemotherapy
If you see any of the following, your skepticism should wake up and start doing push-ups:
- One number for all cancers: “Chemo works 2% of the time” (or any single percentage) applied universally is a red flag.
- Cherry-picked endpoints: Using only 5-year survival to dismiss symptom relief, progression delay, or recurrence reduction.
- Conspiracy framing: “Doctors know chemo doesn’t work but prescribe it anyway.” (This is usually followed by a link to a webshop.)
- Miracle substitution: “You don’t need chemojust take this supplement/juice/IV vitamin regimen.”
- Misused anecdotes: Stories can be powerful, but they don’t replace controlled trials and careful data.
Practical, evidence-based perspective: the questions that actually matter
For patients and families, the most helpful conversations aren’t “Is chemo good or bad?” but:
- What is the goal here? Cure, shrink before surgery, reduce recurrence risk, prolong survival, relieve symptoms?
- What’s the expected benefit for this cancer and stage? In plain language, with numbers where possible.
- What are the major risks and how do we manage them?
- Are there alternatives? Targeted therapy, immunotherapy, hormone therapy, radiation, clinical trials, or supportive care alone?
- How will we know it’s working? Scans, tumor markers, symptoms, functional status, and quality-of-life measures.
This is also why second opinionsespecially at comprehensive cancer centerscan be valuable. Not because your first doctor is “hiding the cure,” but
because complex decisions benefit from additional expertise and perspective.
Experiences from the real world: what “chemo works” can look like
If you hang around infusion centers long enoughpatients, caregivers, nurses, pharmacists, oncologistsyou learn that chemotherapy isn’t a single story.
It’s more like a shelf of books with the same word in the title, but wildly different plots.
There’s the young man with testicular cancer who walks in looking healthy and slightly annoyed (partly at cancer, partly at the hospital gown that never
fits right). He’s terrified, of course, but he’s also hearing something surprisingly hopeful: many cases are highly treatable, and cure rates can be
excellent. His “chemo experience” becomes a sprinthard weeks, strict follow-ups, and then, often, a return to life with an extra layer of gratitude and
a suspicious dislike of the smell of alcohol swabs.
Then there’s the parent of a child with ALL. Their relationship with time changes overnight. Days become lab values. Weeks become cycles. The vocabulary
expands: “neutropenia,” “port access,” “maintenance therapy.” You see families learn how to celebrate tiny milestones: a fever that turns out to be
nothing, a blood count that rebounds, a scan that looks better. They also carry a quiet fatigue that doesn’t photograph well for social media. When
treatment works, the victory isn’t cinematicit’s school pickup, birthdays, and the miracle of ordinary mornings.
For many adults, chemo is less a sprint and more a chess match. A person with colon cancer might describe the strange emotional whiplash of “successful”
surgery followed by a recommendation for months of adjuvant therapy. To outsiders it can sound backward: “If they got it all out, why poison the body?”
But patients often learn the real reason: the fear of recurrence. The chemo days can feel repetitiveinfusion chair, warm blanket, the beep of pumps,
the nurse who remembers your favorite vein. Side effects become a personal weather system. Some people breeze through with mild fatigue; others juggle
neuropathy, appetite changes, and the kind of tiredness that sleep doesn’t fix. Still, many choose it because “working” in this context means stacking
the odds in their favor for the years ahead.
In metastatic disease, “working” can mean something even more human: the ability to breathe easier, to eat without pain, to attend a wedding, to finish
a project, to hold a new grandchild. People sometimes talk about chemo as if the only acceptable outcome is a cure. But many patients measure success in
calendar pages and in moments. They’ll tell you the tradeoffs are real and deeply personal. Some decide a modest survival benefit isn’t worth a harsh
regimen; others decide it is. The best oncology care respects both choicesand helps patients make them with clear information rather than fear.
And nearly everyone has a “supportive care” subplot: the anti-nausea meds that finally make food taste like food again, the steroids that bring a burst
of energy (and occasionally the urge to reorganize a closet at 2 a.m.), the nurse who catches a dangerous symptom early, the friend who quietly handles
rides and meals without turning it into a motivational poster. These experiences don’t erase the hardship of chemotherapy. They do, however, reveal why
simplistic claims like “chemo doesn’t work” feel so disconnected from reality to people who’ve actually lived it.
Bottom line
Chemotherapy is not a universal cure, and it’s not a universal failure. It is a powerful set of toolssometimes curative, sometimes life-prolonging,
sometimes symptom-relieving, often used in combination with other therapies. The “chemo doesn’t work” claim survives because it’s easy to say and hard
to fact-check in a scroll. But when you look at real outcomes, real indications, and real data, the more accurate statement is:
Chemotherapy workswhen it’s the right treatment for the right cancer at the right time, with clear goals and evidence behind it.
